The West Virginia House of Delegates and Mississippi House of Representatives have both approved bills to support research in hopes of gaining federal Food and Drug Administration (FDA) approval for the psychedelic ibogaine as a novel treatment option.
In West Virginia, the legislation from Del. Ryan Browning (R) unanimously passed the House in a 96-0 vote on Thursday, sending it to the Senate for consideration. The similar Mississippi legislation passed that legislature’s House in an 111-1 vote earlier this month.
The research programs envisioned under both measures would focus on supporting trials that look at ibogaine as a treatment option for opioid use disorder, co-occurring substance use disorder and “any other neurological or mental health conditions” for which the psychedelic “demonstrates efficacy.”
Under the West Virginia bill, the secretary of the state Department of Health would be tasked with issuing a notice of funding opportunities under the program, allowing eligible applicants to submit their bids to participate in the research initiative.
An eligible applicant must be a “for-profit, nonprofit, or public benefit corporate entity that has the requisite organizational and financial capacity” to conduct FDA drug development trials and seek approval from FDA to develop ibogaine therapies.
They must also
Read full article on Marijuana Moment
